Category: Press Releases

Press Releases

Over 40% of Adults Struggle to Swallow Pills – BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies

Dec 17, 2025

VANCOUVER, BC / ACCESS Newswire / December 17, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Advances “Melt in Your Mouth” Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia

Dec 9, 2025

VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your...

Continue Reading

Press Releases

BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform

Nov 20, 2025

VANCOUVER, BC / ACCESS Newswire / November 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased...

Continue Reading

Press Releases

BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies

Nov 4, 2025

VANCOUVER, BC / ACCESS Newswire / November 4, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor...

Continue Reading

Press Releases

BioNxt Reports “Readiness to Grant“ Patent Notification from the Eurasian Patent Organization

Oct 30, 2025

VANCOUVER, BC / ACCESSWIRE / October 30, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience innovator specializing in advanced...

Continue Reading

Press Releases

BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study

Oct 21, 2025

Vancouver, Canada (October 21, 2025) – BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT | OTCQB: BNXTF | FSE: BXT), a bioscience innovator specializing...

Continue Reading

Press Releases

BioNxt Completes “Fast-Track” US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis

Oct 13, 2025

VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, today...

Continue Reading

Press Releases

BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform

Oct 2, 2025

VANCOUVER, BC / ACCESS Newswire / October 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in advanced drug-delivery technologies, is pleased...

Continue Reading

Press Releases

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization

Sep 29, 2025

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased...

Continue Reading

Press Releases

BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development

Sep 16, 2025

VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials...

Continue Reading

Press Releases

BioNxt Solutions Completes Up-Listing to The OTCQB Market

Sep 5, 2025

VANCOUVER, BC / ACCESS Newswire / September 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT), is pleased to announce that the common shares of the...

Continue Reading

Press Releases

Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt

Sep 2, 2025

VANCOUVER, BC / ACCESS Newswire / September 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT) is pleased to announce the receipt of the Semaglutide...

Continue Reading